







Atlas Genet Cytogenet Oncol Haematol. 2014; 18(11) 859 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS 
 
OPEN ACCESS JOURNAL 
t(9;12)(q34;p13) ETV6/ABL1 
Etienne De Braekeleer, Nathalie Douet-Guilbert, Marc De Braekeleer 
Cytogenetics Laboratory, Faculty of Medicine, University of Brest, France (EDB, NDG, MDB) 
 
Published in Atlas Database: March 2014 
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t912ID1080.html 
DOI: 10.4267/2042/54172 
This article is an update of : 
Heerema NA. t(9;12)(q34;p13). Atlas Genet Cytogenet Oncol Haematol 2001;5(1):42-43. 
 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
 
Abstract 
Review on t(9;12)(q34;p13) ETV6/ABL1, with data 
on clinics, and the genes implicated. 
Clinics and pathology 
Disease 
Malignant hemopathies (26 cases reported) 
Phenotype/cell stem origin 
AML (3 cases), B-cell ALL (8 cases), T-cell ALL 
(1 case), RAEB evolving into AML (1 case), 
chronic myeloproliferative neoplasm (2 cases), 
Philadelphia chromosome-negative CML (11 
cases). 
Epidemiology 
Gender: 17 males, 8 females; age at diagnosis: 8 
months to 81 years. 
Clinics 
Eosinophilia appears to be a common feature of 
malignancies associated with the ETV6-ABL1 
fusion gene (15/20 cases). 
Genetics 
Note 
The t(9;12)(q34;p13) involves the ETV6 gene 
(12p13), a transcription factor frequently rearranged 
in myeloid and lymphoid leukemias. More than 30 
ETV6 fusion gene partners have been described. 
Most translocations involving ETV6 generate 
fusion genes that lead to the activation of 
transcription factors or kinases but other 
mechanisms are also known (loss of function of the 
fusion gene affecting ETV6 and the partner gene, 
activation of a proto-oncogene in the vicinity of a 
chromosomal translocation and dominant negative 
effect of the fusion protein over transcriptional 
repression mediated by wild-type ETV6). 
Cytogenetics 
Note 
t(9;12)(q34;p13) as the sole abnormality or 
associated with other abnormalities. 
Cytogenetics morphological 
t(9;12)(q34;p13) is very difficult to be identified by 
conventional cytogenetics. 
Cytogenetics molecular 
t(9;12)(q34;p13) usually requires FISH analysis 
with ETV6 and ABL1 probes to be detected 
(cryptic translocation). Insertions are also 
frequently identified. 
Additional anomalies 
Additional anomalies are frequent but show no 
consistent features (trisomies and monosomies of 
various chromosomes, structural rearrangements 
including deletions and translocations). 
Variants 
t(9;12;14)(q34;p13;q22) (seen in conventional 
cytogenetics), 
t(8;9;12)(p12;q34;p13) (seen in conventional 
cytogenetics), 
ins(9;12)(q34;p13p13) (seen by molecular 
cytogenetics), 
ins(12;9)(p13;q34q34) (seen by molecular 
cytogenetics). 
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Schematic diagram of the ETV6, ABL1 and ETV6-ABL1 proteins. 
 
Genes involved and 
proteins 
Note 
As both genes have opposite orientation in relation 
to the centromeres, an in frame ETV6-ABL1 fusion 






The ETV6 gene encodes a transcription factor 
frequently rearranged in myeloid and lymphoid 
leukemias. 
DNA/RNA 
The ETV6 gene spans a region of less than 250 kb 
at band 12p13.1 and consists of 8 exons.  
There are two start codons, one (exon 1a starting at 
codon 1) located at the beginning of the gene and 
another alternative (exon 1b starting at codon 43) 
upstream of exon 3. 
Protein 
The ETV6 protein (452 amino acids) contains two 
major domains, the HLH (helix-loop-helix) and 
ETS domains.  
The HLH domain, also referred to as the pointed or 
sterile alpha motif domain, is encoded by exons 3 
and 4 and functions as a homo-oligodimerization 
domain. The ETS domain, encoded by exons 6 
through 8, is responsible for sequence specific 





The ABL1 gene, spanning a 230-kb region at band  
9q34, includes the 5' alternative first exons 1b and 
1a and ten common exons numbered from 2 to 11. 
Alternative splicing using exons 1b and 1a gives 
rise to mRNA of 7 and 6 kb, respectively. 
Protein 
The ABL1 protein has three SRC homology (SH) 
domains called SH1, SH2 and SH3, of which SH1 
that has a tyrosine kinase function.  
The SH2 and SH3 domains are involved in protein-
protein interactions, which regulate the tyrosine 
kinase activity; they are necessary for signal 
transduction function.  
The ABL1 protein has also three nuclear 
localization signal domains and three DNA binding 
regions and an F-actin binding domain. 




Two ETV6-ABL1 transcripts were identified in 
most of the patients, one joining exon 5 of ETV6 to 
exon 2 of ABL1, the other, usually found at very 
low levels, joining ETV6 exon 4 to ABL1 exon 2. 
Fusion protein 
Description 
The fusion protein retains all three SH domains, 
including the tyrosine kinase domain, of ABL1, 
which make these patients sensitive to tyrosine 
kinase inhibitors.  
The retained N-terminal part of the ETV6 protein 
contains the helix-loop-helix domain necessary for 
oligomerization of the protein, which is required for 
tyrosine kinase activation, cytoskeletal localization 
and neoplastic transformation. 
Oncogenesis 
Constitutive tyrosine kinase activation of ABL1. 
 






Atlas Genet Cytogenet Oncol Haematol. 2014; 18(11) 861 
References 
Papadopoulos P, Ridge SA, Boucher CA, Stocking C, 
Wiedemann LM. The novel activation of ABL by fusion to 
an ets-related gene, TEL. Cancer Res. 1995 Jan 
1;55(1):34-8 
Baens M, Peeters P, Guo C, Aerssens J, Marynen P. 
Genomic organization of TEL: the human ETS-variant 
gene 6. Genome Res. 1996 May;6(5):404-13 
Brunel V, Sainty D, Carbuccia N, Mozzicconacci M, 
Fernandez F, Simonetti J, Gabert J, Dubreuil P, Lafage-
Pochitaloff M, Birg F.. A TEL/ABL fusion gene on 
chromosome 12p13 in a case of Ph-, BCR-atypical CML. 
Leukemia 1996; 10: 2003. 
Golub TR, Goga A, Barker GF, Afar DE, McLaughlin J, 
Bohlander SK, Rowley JD, Witte ON, Gilliland DG.. 
Oligomerization of the ABL tyrosine kinase by the Ets 
protein TEL in human leukemia. Mol Cell Biol. 1996 
Aug;16(8):4107-16. 
Andreasson P, Johansson B, Carlsson M, Jarlsfelt I, 
Fioretos T, Mitelman F, Hoglund M.. BCR/ABL-negative 
chronic myeloid leukemia with ETV6/ABL fusion. Genes 
Chromosomes Cancer. 1997 Nov;20(3):299-304. 
Mavrothalassitis G, Ghysdael J.. Proteins of the ETS 
family with transcriptional repressor activity. Oncogene. 
2000 Dec 18;19(55):6524-32. (REVIEW) 
Van Limbergen H, Beverloo HB, van Drunen E, Janssens 
A, Hahlen K, Poppe B, Van Roy N, Marynen P, De Paepe 
A, Slater R, Speleman F.. Molecular cytogenetic and 
clinical findings in ETV6/ABL1-positive leukemia. Genes 
Chromosomes Cancer. 2001 Mar;30(3):274-82. 
Keung YK, Beaty M, Steward W, Jackle B, Pettnati M.. 
Chronic myelocytic leukemia with eosinophilia, 
t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: 
case report and review of the literature. Cancer Genet 
Cytogenet. 2002 Oct 15;138(2):139-42. (REVIEW) 
La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, 
Crescenzi B, Martelli M, Flandrin G, Pelicci PG, Mecucci 
C.. Clonal eosinophils are a morphologic hallmark of 
ETV6/ABL1 positive acute myeloid leukemia. 
Haematologica. 2002 Aug;87(8):789-94. 
Lin H, Guo JQ, Andreeff M, Arlinghaus RB.. Detection of 
dual TEL-ABL transcripts and a Tel-Abl protein containing 
phosphotyrosine in a chronic myeloid leukemia patient. 
Leukemia. 2002 Feb;16(2):294-7. 
O'Brien SG, Vieira SA, Connors S, Bown N, Chang J, 
Capdeville R, Melo JV.. Transient response to imatinib 
mesylate (STI571) in a patient with the ETV6-ABL t(9;12) 
translocation. Blood. 2002 May 1;99(9):3465-7. 
Barbouti A, Ahlgren T, Johansson B, Hoglund M, Lassen 
C, Turesson I, Mitelman F, Fioretos T.. Clinical and genetic 
studies of ETV6/ABL1-positive chronic myeloid leukaemia 
in blast crisis treated with imatinib mesylate. Br J 
Haematol. 2003 Jul;122(1):85-93. 
Meyer-Monard S, Muhlematter D, Streit A, Chase AJ, 
Gratwohl A, Cross NC, Jotterand M, Tichelli A.. Broad 
molecular screening of an unclassifiable myeloproliferative 
disorder reveals an unexpected ETV6/ABL1 fusion 
transcript. Leukemia. 2005 Jun;19(6):1096-9. 
Tirado CA, Sebastian S, Moore JO, Gong JZ, Goodman 
BK.. Molecular and cytogenetic characterization of a novel 
rearrangement involving chromosomes 9, 12, and 17 
resulting in ETV6 (TEL) and ABL fusion. Cancer Genet  
 
Cytogenet. 2005 Feb;157(1):74-7. 
Mozziconacci MJ, Sainty D, Chabannon C.. A fifteen-year 
cytogenetic remission following interferon treatment in a 
patient with an indolent ETV6-ABL positive 
myeloproliferative syndrome. Am J Hematol. 2007 
Jul;82(7):688-9. 
Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, 
Ottmann OG, Nijmeijer BA.. Establishment and cytogenetic 
characterization of a human acute lymphoblastic leukemia 
cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer 
Genet Cytogenet. 2008 Aug;185(1):37-42. doi: 
10.1016/j.cancergencyto.2008.05.001. 
Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, 
Schreck R, Moore S, Ogawa S.. Chronic phase of ETV6-
ABL1 positive CML responds to imatinib. Genes 
Chromosomes Cancer. 2008 Oct;47(10):919-21. doi: 
10.1002/gcc.20593. 
Kelly JC, Shahbazi N, Scheerle J, Jahn J, Suchen S, 
Christacos NC, Mowrey PN, Witt MH, Hostetter A, Meloni-
Ehrig AM.. Insertion (12;9)(p13;q34q34): a cryptic 
rearrangement involving ABL1/ETV6 fusion in a patient 
with Philadelphia-negative chronic myeloid leukemia. 
Cancer Genet Cytogenet. 2009 Jul;192(1):36-9. doi: 
10.1016/j.cancergencyto.2009.02.012. 
Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah 
E.. Myeloproliferative disorder with eosinophilia and ETV6-
ABL gene rearrangement: efficacy of second-generation 
tyrosine kinase inhibitors. Leuk Res. 2009 Aug;33(8):1144-
6. doi: 10.1016/j.leukres.2009.03.011. Epub 2009 Apr 25. 
Malone A, Langabeer S, O'Marcaigh A, Storey L, Bacon 
CL, Smith OP.. A doctor(s) dilemma: ETV6-ABL1 positive 
acute lymphoblastic leukaemia. Br J Haematol. 2010 
Oct;151(1):101-2. doi: 10.1111/j.1365-2141.2010.08323.x. 
Epub 2010 Jul 7. 
Zuna J, Zaliova M, Muzikova K, Meyer C, Lizcova L, 
Zemanova Z, Brezinova J, Votava F, Marschalek R, Stary 
J, Trka J.. Acute leukemias with ETV6/ABL1 (TEL/ABL) 
fusion: poor prognosis and prenatal origin. Genes 
Chromosomes Cancer. 2010 Oct;49(10):873-84. doi: 
10.1002/gcc.20796. 
De Braekeleer E1, Douet-Guilbert N, Rowe D, Bown N, 
Morel F, Berthou C, Ferec C, De Braekeleer M.. ABL1 
fusion genes in hematological malignancies: a review. Eur 
J Haematol. 2011 May;86(5):361-71. doi: 10.1111/j.1600-
0609.2011.01586.x. Epub 2011 Mar 23. (REVIEW) 
Perna F, Abdel-Wahab O, Levine RL, Jhanwar SC, Imada 
K, Nimer SD.. ETV6-ABL1-positive "chronic myeloid 
leukemia": clinical and molecular response to tyrosine 
kinase inhibition. Haematologica. 2011 Feb;96(2):342-3. 
doi: 10.3324/haematol.2010.036673. Epub 2010 Dec 29. 
De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, 
Basinko A, De Braekeleer M.. ETV6 fusion genes in 
hematological malignancies: a review. Leuk Res. 2012 
Aug;36(8):945-61. doi: 10.1016/j.leukres.2012.04.010. 
Epub 2012 May 12. (REVIEW) 
Zhou MH, Gao L, Jing Y, Xu YY, Ding Y, Wang N, Wang 
W, Li MY, Han XP, Sun JZ, Wang LL, Yu L.. Detection of 
ETV6 gene rearrangements in adult acute lymphoblastic 
leukemia. Ann Hematol. 2012 Aug;91(8):1235-43. doi: 
10.1007/s00277-012-1431-4. Epub 2012 Feb 29. 
This article should be referenced as such: 
De Braekeleer E, Douet-Guilbert N, De Braekeleer M. 
t(9;12)(q34;p13) ETV6/ABL1. Atlas Genet Cytogenet 
Oncol Haematol. 2014; 18(11):859-861. 
